Search

This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.

This book reviews the relationship between cytokines, glia, and neurons in the pathophysiology of neuropsychiatric disorders and examines the mechanisms of action of the drugs used for the treatment of these disorders. Increasing evidence has suggested that glia perform important roles in various brain functions, but much remains to be learned about these crucial cells and their interplay with neurons. In addition, a better understanding of the interaction between inflammatory mediators, such as cytokines, and the activated immune response will be of critical importance for the development of new therapeutic strategies. These key areas are the focus of this book, which documents the latest research findings in the field. Evidence is provided for the role of inflammation-induced toxic metabolites from the tryptophan pathway in a wide range of neuropsychiatric disorders, including depression, schizophrenia, and Alzheimer's disease. In presenting state of the art knowledge on the interactions between cytokines, glia, and neurons, the book will help to pave the way for the development of novel targets for the prevention and treatment of neuropsychiatric disorders.

This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.

This book reviews all important aspects of anxiety disorders with the aim of shedding new light on these disorders through combined understanding of traditional and novel paradigms. The book is divided into five sections, the first of which reinterprets anxiety from a network science perspective, examining the altered topological properties of brain networks in anxiety disorders. The second section discusses recent advances in understanding of the neurobiology of anxiety disorders, covering, for example, gene-environmental interactions and the roles of neurotransmitter systems and the oxytocin system. A wide range of diagnostic and clinical issues in anxiety disorders are then addressed, before turning attention to contemporary treatment approaches in the context of novel bio-psychosocial-behavioral models, including bio- and neurofeedback, cognitive behavioral therapy, neurostimulation, virtual reality exposure therapy, pharmacological interventions, psychodynamictherapy, and CAM options. The final section is devoted to precision psychiatry in anxiety disorders, an increasingly important area as we move toward personalized treatment.Anxiety Disorders will be of interest for all researchers and clinicians in the field.

This book reviews key recent advances and new frontiers within psychiatric research and clinical practice. These advances either represent or are enabling paradigm shifts in the discipline and are influencing how we observe, derive and test hypotheses, and intervene. Progress in information technology is allowing the collection of scattered, fragmented data and the discovery of hidden meanings from stored data, and the impacts on psychiatry are fully explored. Detailed attention is also paid to the applications of artificial intelligence, machine learning, and data science technology in psychiatry and to their role in the development of new hypotheses, which in turn promise to lead to new discoveries and treatments. Emerging research methods for precision medicine are discussed, as are a variety of novel theoretical frameworks for research, such as theoretical psychiatry, the developmental approach to the definition of psychopathology, and the theory of constructed emotion. Theconcluding section considers novel interventions and treatment avenues, including psychobiotics, the use of neuromodulation to augment cognitive control of emotion, and the role of the telomere-telomerase system in psychopharmacological interventions.

This book reviews all the important aspects of treatment-resistant psychiatric disorders, covering issues such as definitions, clinical aspects, neurobiological correlates, treatment options, and predictors of treatment response. The book is divided into three sections, the first of which examines the most recent thinking on treatment resistance in psychiatry, including definition and epidemiology, paradigm shift in the study of the subjects, individual susceptibility and resilience, abnormal structural or functional connectivity, and insights from animal models. The second section then discusses treatment resistance in each of the major psychiatric disorders, with particular focus on the responsible clinical and biological factors and the available management strategies. Finally, more detailed information is presented on diverse pharmacological and non-pharmacological therapeutic interventions. The book, written by leading experts from across the world, will be of value to all who seek a better understanding of the clinical-neurobiological underpinnings and the development of management for treatment resistance in psychiatric disorders.

This book, in two volumes, focuses on contemporary issues and dilemmas in relation to depression. The aim is to equip readers with an up-to-date understanding of the clinical and neurobiological underpinnings of depression and their relation to clinical manifestations and the development of more effective treatments. This first volume is devoted specifically to biomedical and neurobiological issues. Detailed information is presented on a wide range of topics, including genetics, molecular and cellular biology, and aspects at the neural circuit and multicellular system levels. Readers will gain a deeper appreciation of the factors and interactions underlying individual variation in responsiveness to stress and vulnerability to depression, as well as a clear understanding of potential treatment targets and causes of treatment resistance based on the latest research. A concluding section considers progress towards precision psychiatry and gender and cultural differences in depression.The companion volume is dedicated to clinical and management issues in depression. Understanding Depression will be an excellent source of information for both researchers and practitioners in the field.

This book, in two volumes, focuses on contemporary issues and dilemmas in relation to depression. The aim is to equip readers with an up-to-date understanding of the clinical and neurobiological underpinnings of depression, the clinical manifestations, and the development of more effective treatments. This second volume is devoted specifically to clinical and management issues. Readers will find detailed information on a wide range of frequently encountered and more complicated clinical presentations, with examination of risk factors and links to other conditions. Diagnostic aspects, including progress toward biological classification and the role of neuroimaging, are explored. Current trends in therapy are examined at length, drawing on the latest evidence and covering not only antidepressant medications but also the roles of neurostimulation, combined pharmacotherapy and psychotherapy, mindfulness-based cognitive therapy, and complementary and alternative medicine. The companion volume is dedicated to the underlying biomedical and neurobiological basis of depression. Understanding Depression will be an excellent source of information for both researchers and practitioners in the field.